Fedotozine, a kappa-opioid agonist, prevents spinal and supra-spinal Fos expression induced by a noxious visceral stimulus in the rat.
Fedotozine, a kappa opioid agonist, reverses digestive ileus caused by acetic acid (AA)-induced visceral pain in rats. The aims of this study were: to map, in conscious rats, central pathways activated by AA using Fos as a marker of neuronal activation; to characterize primary afferent fibres involved in this activation; and to investigate the effect of fedotozine on AA-induced Fos expression. AA (0.6%; 10 mL kg-1) was injected i.p. in conscious rats either untreated; pretreated 14 days before with capsaicin; pretreated 20 min previously with fedotozine; or pretreated 2 h prior to fedotozine with the kappa-antagonist nor-binaltorphimine (nor-BNI). Controls received the vehicle alone. 60 min after injection of AA, rats were processed for Fos immunohistochemistry. Visceral pain was assessed by counting abdominal cramps. AA induced Fos in the thoraco-lumbar spinal cord (laminae I, V, VII and X) and numerous brain structures such as the nucleus tractus solitarius, and paraventricular nucleus (PVN) of the hypothalamus, whereas almost no Fos labelling was observed in controls. Capsaicin pretreatment blocked AA-induced Fos in all structures tested. Fedotozine significantly decreased AA-induced abdominal cramps and Fos immunoreactivity in the spinal cord and PVN, this effect being reversed by nor-BNI pretreatment. AA induces Fos in the spinal cord and numerous brain nucuei, some of which are involved in the control of digestive motility in rats. This effect is mediated through capsaicin-sensitive afferent fibres and prevented by fedotozine most likely through a peripheral action on visceral afferents.
Bonaz
B
B
Laboratoire de Physiologie, Section Neurophysiologie, Institut National de la Santé et de la Recherche Médicale, U318, Hôpital A. Michallon, Centre Hospitalier Universitaire, Grenoble, France. bruno.bonaz@ujf-grenoble.fr
Rivière
P J
PJ
Sinniger
V
V
Pascaud
X
X
Junien
J L
JL
Fournet
J
J
Feuerstein
C
C
D015746:Abdominal Pain / Q000139:chemically induced / Q000378:metabolism* / Q000517:prevention & control; D019342:Acetic Acid / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000633:toxicity; D000344:Afferent Pathways / Q000187:drug effects; D000818:Animals; D001593:Benzyl Compounds / Q000494:pharmacology* / Q000627:therapeutic use; D001921:Brain / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D002211:Capsaicin / Q000494:pharmacology / Q000627:therapeutic use; D005786:Gene Expression Regulation / Q000187:drug effects*; D016762:Genes, fos; D007274:Injections, Intraperitoneal; D007415:Intestinal Obstruction / Q000139:chemically induced / Q000378:metabolism*; D008297:Male; D009271:Naltrexone / Q000031:analogs & derivatives / Q000494:pharmacology; D010286:Paraventricular Hypothalamic Nucleus / Q000187:drug effects / Q000378:metabolism; D011437:Propylamines / Q000494:pharmacology* / Q000627:therapeutic use; D016760:Proto-Oncogene Proteins c-fos / Q000096:biosynthesis*; D051381:Rats; D017207:Rats, Sprague-Dawley; D017473:Receptors, Opioid, kappa / Q000819:agonists / Q000037:antagonists & inhibitors / Q000502:physiology*; D017552:Solitary Nucleus / Q000187:drug effects / Q000378:metabolism; D013116:Spinal Cord / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D013495:Supraoptic Nucleus / Q000187:drug effects / Q000378:metabolism
D001593:Benzyl Compounds; D011437:Propylamines; D016760:Proto-Oncogene Proteins c-fos; D017473:Receptors, Opioid, kappa; C051844:norbinaltorphimine; D009271:Naltrexone; C067749:fedotozine; D019342:Acetic Acid; D002211:Capsaicin